Stock Track | Taysha Gene Therapies Soars 5.39% Pre-market on Positive Analyst Ratings and Q3 Results

Stock Track11-05

Taysha Gene Therapies, Inc. (TSHA) stock surged 5.39% in pre-market trading on Wednesday, following a series of positive analyst ratings and the release of encouraging third-quarter results. The gene therapy company's shares are gaining momentum as multiple financial firms express confidence in its potential.

Leading the optimistic outlook, Jefferies raised its price target for Taysha Gene Therapies from $9 to $11. This upgrade was complemented by Truist Financial and Chardan Capital both maintaining their Buy ratings on the stock. Additionally, Citizens upheld its Market Outperform rating, further bolstering investor confidence in the company's prospects.

The pre-market rally also appears to be fueled by Taysha's recent Q3 earnings release, which highlighted advancements in its TSHA-102 program. This progress in the company's gene therapy pipeline suggests promising developments that could drive future growth and market performance. As investors digest these positive signals, Taysha Gene Therapies seems well-positioned for potential further gains.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161172815?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161172815","market":"nz","top_or_hot":-1,"title":"Stock Track | Taysha Gene Therapies Soars 5.39% Pre-market on Positive Analyst Ratings and Q3 Results","media":"Stock Track","content":"<p>Taysha Gene Therapies, Inc. (TSHA) stock surged 5.39% in pre-market trading on Wednesday, following a series of positive analyst ratings and the release of encouraging third-quarter results. The gene therapy company's shares are gaining momentum as multiple financial firms express confidence in its potential.</p>\n\n<p>Leading the optimistic outlook, Jefferies raised its price target for Taysha Gene Therapies from $9 to $11. This upgrade was complemented by Truist Financial and Chardan Capital both maintaining their Buy ratings on the stock. Additionally, Citizens upheld its Market Outperform rating, further bolstering investor confidence in the company's prospects.</p>\n\n<p>The pre-market rally also appears to be fueled by Taysha's recent Q3 earnings release, which highlighted advancements in its TSHA-102 program. This progress in the company's gene therapy pipeline suggests promising developments that could drive future growth and market performance. As investors digest these positive signals, Taysha Gene Therapies seems well-positioned for potential further gains.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Taysha Gene Therapies Soars 5.39% Pre-market on Positive Analyst Ratings and Q3 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Taysha Gene Therapies Soars 5.39% Pre-market on Positive Analyst Ratings and Q3 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 22:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Taysha Gene Therapies, Inc. (TSHA) stock surged 5.39% in pre-market trading on Wednesday, following a series of positive analyst ratings and the release of encouraging third-quarter results. The gene therapy company's shares are gaining momentum as multiple financial firms express confidence in its potential.</p>\n\n<p>Leading the optimistic outlook, Jefferies raised its price target for Taysha Gene Therapies from $9 to $11. This upgrade was complemented by Truist Financial and Chardan Capital both maintaining their Buy ratings on the stock. Additionally, Citizens upheld its Market Outperform rating, further bolstering investor confidence in the company's prospects.</p>\n\n<p>The pre-market rally also appears to be fueled by Taysha's recent Q3 earnings release, which highlighted advancements in its TSHA-102 program. This progress in the company's gene therapy pipeline suggests promising developments that could drive future growth and market performance. As investors digest these positive signals, Taysha Gene Therapies seems well-positioned for potential further gains.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TSHA","symbol_name":"Taysha Gene Therapies, Inc.","start_time":0,"source_url":"","article_id":"1161172815","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161172815","pubTimestamp":1762353063,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Taysha Gene Therapies, Inc. (TSHA) stock surged 5.39% in pre-market trading on Wednesday, following a series of positive analyst ratings and the release of encouraging third-quarter results. The gene...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TSHA":"Taysha Gene Therapies, Inc."},"translate_title":"个股追踪|Taysha Gene Therapies盘前飙升5.39%，因分析师正面评级和Q3业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSHA":1},"content_text":"Taysha Gene Therapies, Inc. (TSHA) stock surged 5.39% in pre-market trading on Wednesday, following a series of positive analyst ratings and the release of encouraging third-quarter results. The gene therapy company's shares are gaining momentum as multiple financial firms express confidence in its potential.\nLeading the optimistic outlook, Jefferies raised its price target for Taysha Gene Therapies from $9 to $11. This upgrade was complemented by Truist Financial and Chardan Capital both maintaining their Buy ratings on the stock. Additionally, Citizens upheld its Market Outperform rating, further bolstering investor confidence in the company's prospects.\nThe pre-market rally also appears to be fueled by Taysha's recent Q3 earnings release, which highlighted advancements in its TSHA-102 program. This progress in the company's gene therapy pipeline suggests promising developments that could drive future growth and market performance. As investors digest these positive signals, Taysha Gene Therapies seems well-positioned for potential further gains.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161172815","isCrawlerRequest":true}